CD4+ T cells are pivotal regulators of adaptive immunity in CRC, exhibiting both anti-tumor and pro-tumor functions depending on their subset differentiation and local microenvironmental cues (Toor et al., 2019; Aristin Revilla et al., 2022; Li et al., 2025; Revilla et al., 2025). The gene discussed is CD4; the disease is neoplasm.